CLINICAL SCIENCE

Metabolic assessment of elderly men with urolithiasis

Celso Heitor Freitas Junior, Eduardo Mazzucchi, Alexandre Danilovic, Artur Henrique Brito, Miguel Srougi

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Urologic Division, São Paulo/SP, Brazil.

OBJECTIVE: To assess the presence of metabolic disorders in elderly men with urolithiasis.

METHODS: We performed a case-control study. The inclusion criteria were as follows: (1) men older than 60 years of age and either (2) antecedent renal colic or an incidental diagnosis of urinary lithiasis after age 60 (case arm) or (3) no antecedent renal colic or incidental diagnosis of urolithiasis (control arm). Each individual underwent an interview, and those who were selected underwent all clinical protocol examinations: serum levels of total and ionized calcium, uric acid, phosphorus, glucose, urea, creatinine and parathyroid hormone, urine culture, and analysis of 24-hour urine samples (levels of calcium, citrate, creatinine, uric acid and sodium, pH and urine volume). Each case arm patient underwent two complete metabolic urinary investigations, whereas each control arm individual underwent one examination. ClinicalTrials.gov: NCT01246531.

RESULTS: A total of 51 subjects completed the clinical investigation: 25 in the case arm and 26 in the control arm. In total, 56% of the case arm patients had hypocitraturia (vs. 15.4% in the control arm; \( p = 0.002 \)). Hypernatriuria was detected in 64% of the case arm patients and in 30.8% of the controls (\( p = 0.017 \)).

CONCLUSION: Hypocitraturia and hypernatriuria are the main metabolic disorders in elderly men with urolithiasis.

KEYWORDS: Urolithiasis; Calculi; Citrate; Metabolism; Aging; Elderly.

INTRODUCTION

The increase in male life expectancy has provoked many inquiries into health disorders and quality of life with respect to the natural aging process. Populational aging is characterized by a higher proportion of people who reach advanced ages combined with shrinking numbers of children and young people in that group. According to the World Health Organization (WHO), aging is defined as living beyond 60 years in a developing country or 65 years in a developed country. The number of aging people is increasing faster than is any other age group: in 2025, there will be an estimated 1.2 billion individuals over the age of 60, and this number could reach two billion by 2050 (1). Urolithiasis is a public health problem affecting approximately 300 men and 100 women out of every 100,000 people (2). At present, the incidence of urolithiasis in aging people is increasing, particularly in industrialized countries (3-5). Little information is available about urolithiasis in older individuals, especially with respect to metabolic disorders that may be helpful for the clinical treatment of these individuals.

MATERIALS AND METHODS

This project was approved by our Hospital Ethics Committee (protocol number 0688/07) in October 2007. It was also registered in Clinical Trials (www.clinicaltrials.gov): NCT01246531. All patients provided written informed consent for their participation in the study. We performed a case-control study with patients who were recruited from a database of the Urologic Clinic between January 2008 and January 2010.

The inclusion criteria for the case arm were applied to patients from the Urinary Lithiasis database: (I) men older than 60 years of age (II) who had a first episode of renal colic (lumbar or flank pain) or an incidental diagnosis of renal stones after age 60. The patients in the control arm were selected from a database of men with benign prostate hyperplasia (BPH). The inclusion criteria were as follows: (I) men older than 60 years of age and (II) with no diagnosis of renal stones at any point in their lives. All patients were asked about their stone disease history (renal colic, age at the first lithiasic episode, incidental urolithiasis diagnosis, antecedent shockwave lithotripsy or surgical therapies for renal and/or ureteral calculi), persistent...
urinary tract infection, family history of renal stones, clinical comorbidities (e.g., hypertension, diabetes, dyslipidemia, gout) and drug use (including alcohol consumption and smoking). All subjects underwent the following metabolic assessments:

- Blood tests: total calcium, ionized calcium, uric acid, phosphorus, glucose, creatinine, urea and parathyroid hormone (PTH) levels;
- Type I urinalysis and urine culture;
- 24-hour urine samples: calcium, citrate, creatinine, uric acid and sodium levels, pH and volume.

Each case arm patient underwent two complete metabolic urinary investigations, and the control arm patients underwent one metabolic urinary investigation with three 24-hour urinary samples, as described previously.

Imaging examinations, including abdominal X-rays, abdominal ultrasonography, and unenhanced abdominal computed tomography (CT) (if necessary), were conducted for documentation purposes.

Frequency analyses and descriptive statistics i.e., mean and standard deviation (SD), were performed. The Student’s t-test was used to compare the case and control arms. The associations between the independent data from the case and control arms were tested using the chi-squared test. If the expected value in any category was less than or equal to five, Fisher’s exact test was performed instead of the chi-squared test. Independent variables that demonstrated statistically significant differences were tested by univariate logistic regression analyses. Multiple logistic regression analysis evaluated the relationship between hypocitraturia and hypernatriuria, adjusting for thiazide use based on our theoretical understanding of the effects of thiazide diuretics on renal metabolism (6). Statistical significance was set at $p<0.05$. All statistical analyses were conducted using SPSS for Windows 18.0 software (Chicago, IL).

RESULTS

After applying the inclusion criteria, 70 patients were selected to participate in the clinical protocol. Nineteen patients did not complete the clinical study, with seventeen lost to follow-up (eight patients from the case arm and nine from the control arm). Two individuals were diagnosed with prostate cancer during the study and were discharged for oncologic management (one from each arm). In total, 51 men completed the protocol: 25 in the case arm and 26 in the control arm.

The two groups were statistically comparable in terms of their demographics, comorbidities, smoking and alcoholic beverage consumption habits, and thiazide use (Table 1).

Twenty patients from the case arm had comorbidities: systemic arterial hypertension ($n=11$), diabetes mellitus ($n=7$), and gout ($n=3$). In the control arm, there were 21 men with comorbidities: systemic arterial hypertension ($n=13$), diabetes mellitus ($n=4$), and gout ($n=1$).

The blood metabolic assessments revealed no significant disorders (Table 2).

The urinary metabolic assessments revealed hypocitraturia in 56.0% of the case arm patients and 15.4% of the control arm patients ($p=0.002$). Hypernatriuria was detected in 64.0% of the case arm patients and in 30.8% of the controls ($p=0.017$). No additional statistically significant differences were present for the remaining variables (Table 3). These findings were confirmed by the univariate analyses and multiple logistic regressions. Hypocitraturia and elevated urinary sodium levels were independent risk factors for urinary lithiasis, even when adjusted for thiazide use (Table 4), which would be considered a confounding factor in the analysis. Another notable observation was the presence of an altered urinary pH in 11 patients of the case arm compared with five individuals from the control arm, a difference that approached statistical significance ($p=0.057$).

Table 1 - Demographics, comorbidities, smoking and alcohol consumption habits and thiazide use.

| Variable               | Cases                  | Controls                | $p$-value |
|------------------------|------------------------|-------------------------|-----------|
| Age (years)            | 68.3 (5.4) (60 – 78)   | 67.8 (5.9) (60 – 83)    | 0.750*    |
| Weight (kg)            | 79.2 (11.7) (59 – 103) | 74.9 (11.0) (60 – 100)  | 0.177*    |
| Race                   | 22 (88.0)              | 24 (92.3)               |           |
| Alcohol consumption    | 17 (68.0)              | 20 (76.9)               |           |
| Yes                    | 8 (32.0)               | 6 (23.1)                |           |
| Smoker                 | 23 (92.0)              | 21 (80.8)               |           |
| Yes                    | 2 (8.0)                | 5 (19.2)                |           |
| Medical disorders      | 5 (20.0)               | 6 (23.1)                |           |
| Yes                    | 20 (80.0)              | 20 (76.9)               |           |
| Thiazide use           | 22 (88.0)              | 20 (76.9)               |           |
| Yes                    | 3 (12.0)               | 6 (23.1)                |           |
| Total                  | 25 (100)               | 26 (100)                |           |

*Student’s T-test; ‘Fisher’s exact test; SD = standard deviation.
Table 2 - Metabolic assessment (blood tests).

| Variable     | Cases          | Controls       | p-value |
|--------------|----------------|----------------|---------|
| Total calcium |               |                |         |
| (RV: 8.6 – 10.2 mg/dl) |                |                |         |
| Normal       | 22 (88.0)      | 25 (96.2)      | 0.350$^1$ |
| High         | 3 (12.0)       | 1 (3.8)        |         |
| Ionized calcium |              |                |         |
| (RV: 4.6 – 5.3 mg/dl) |                |                |         |
| Normal       | 22 (88.0)      | 24 (92.4)      | 0.668$^1$ |
| High         | 3 (12.0)       | 2 (7.7)        |         |
| Uric acid    |               |                |         |
| (RV: 3.4 – 7.0 mg/dl) |                |                |         |
| Normal       | 20 (80.0)      | 20 (76.9)      | 0.789*  |
| High         | 5 (20.0)       | 6 (23.1)       |         |
| Phosphorus   |               |                |         |
| (RV: 2.7 – 4.5 mg/dl) |                |                |         |
| Normal       | 20 (80.0)      | 20 (76.9)      | 0.789*  |
| Low          | 5 (20.0)       | 6 (23.1)       |         |
| Glucose      |               |                |         |
| (RV: 65 – 99 mg/dl) |               |                |         |
| Normal       | 10 (40.0)      | 9 (34.6)       | 0.691*  |
| High         | 16 (60.0)      | 17 (65.4)      |         |
| Urea         |               |                |         |
| (RV: 10 – 50 mg/dl) |               |                |         |
| Normal       | 22 (88.0)      | 25 (96.2)      | 0.350$^1$ |
| High         | 3 (12.0)       | 1 (3.8)        |         |
| Creatinine   |               |                |         |
| (RV: 0.6 – 1.5 mg/dl) |               |                |         |
| Normal       | 23 (92.0)      | 25 (96.2)      | 0.610$^1$ |
| High         | 2 (8.0)        | 1 (3.8)        |         |
| Sodium       |               |                |         |
| (RV: 100 – 240 mg) |               |                |         |
| Normal       | 22 (88.0)      | 18 (69.2)      | 0.103*  |
| High         | 3 (12.0)       | 8 (30.8)       |         |
| Citrate      |               |                |         |
| (RV: > 290 mg) |               |                |         |
| Normal       | 11 (44.0)      | 22 (84.6)      | 0.002*  |
| Low          | 14 (56.0)      | 4 (15.4)       |         |
| Uric acid    |               |                |         |
| (RV: 0.2 – 0.75 g) |               |                |         |
| Normal       | 20 (80.0)      | 23 (85.5)      | 0.465$^1$ |
| High         | 5 (20.0)       | 3 (11.5)       |         |
| Uric acid    |               |                |         |
| (RV: > 0.2 ml/kg/day) |               |                |         |
| Normal       | 17 (70.8)      | 21 (80.8)      | 0.411*  |
| Low          | 7 (29.2)       | 5 (19.5)       |         |
| pH           |               |                |         |
| (RV: 6 – 7)  |               |                |         |
| Normal       | 14 (56.0)      | 21 (80.8)      | 0.057*  |
| Altered      | 11 (44.0)      | 5 (19.2)       |         |
| Citrate      |               |                |         |
| (RV: Negative) |               |                |         |
| Negative     | 23 (92.0)      | 22 (84.6)      | 0.668$^1$ |
| Positive     | 2 (8.0)        | 4 (15.4)       |         |
| Total        | 25 (100)       | 26 (100)       |         |

RV = reference value.

**Discussion**

Urinary lithiasis in elderly people has an estimated prevalence of 10–12% and an estimated incidence of 0.1–2% (7). In Japan, the prevalence reaches almost 9.6% and predominantly affects men (71.7%) (8). No consensus exists on the worldwide prevalence of urolithiasis in aging individuals, and even given the recent increase in incidence, there are few studies on this subject in the urological literature.

Urolithiasis is a disorder that may cause a higher morbidity rate in older people than in younger people, mainly due to urinary obstruction related to stone migration and infectious complications (9). Recently, some authors have assessed the aspects and outcomes of extracorporeal shock wave lithotripsy (SWL) (10-14), percutaneous nephrolithotomy (15-17) and ureteroscopy (18) for elderly patients with renal or ureteral stones. However, no recent studies have involved metabolic assessments of urinary lithiasis in aging subjects.

We performed a case-control study that was initially designed as a pilot study with 70 patients. Unfortunately, we lost almost 25% of our sample, which is higher than the normal attrition rate of 10% reported in a majority of studies. Most patients who stopped the study cited the 24-hour urine gathering protocol and transportation to the clinical laboratory as their main reasons for withdrawal. A case-control study design was selected because the sample size was small (because urinary lithiasis is not common in aging people) and no comparative studies existed on metabolic assessments in aging men with urolithiasis. Another advantage of the case-control design is its ability to evaluate the feasibility of more complex and expensive future projects.

The control arm did include individuals with BPH, which could have introduced possible selection bias (e.g., limited fluid intake due to nocturia and/or urinary frequency). Patients from the control arm were asymptomatic during the study, and the case arm were asymptomatic during the study, and no increase in urinary lithiasis events (20).

None of the patients had undergone gastric bypass surgery, another potential cause of hyperoxaluria, which could have resulted in confounding. All individuals from the case arm were asymptomatic during the study, and radiologic examinations did not reveal any obstructive

Table 3 - Metabolic assessment: 24-hour urine samples and urine culture.

| Variable     | Cases          | Controls       | p-value |
|--------------|----------------|----------------|---------|
| Calcium      |               |                |         |
| (RV: 100 – 240 mg) |               |                |         |
| Normal       | 22 (88.0)      | 18 (69.2)      | 0.103*  |
| High         | 3 (12.0)       | 8 (30.8)       |         |
| Citrate      |               |                |         |
| (RV: > 290 mg) |               |                |         |
| Normal       | 11 (44.0)      | 22 (84.6)      | 0.002*  |
| Low          | 14 (56.0)      | 4 (15.4)       |         |
| Creatinine   |               |                |         |
| (RV: 0.2 ml/kg/day) |               |                |         |
| Normal       | 20 (80.0)      | 23 (85.5)      | 0.465$^1$ |
| High         | 5 (20.0)       | 3 (11.5)       |         |
| Uric acid    |               |                |         |
| (RV: > 0.2 ml/kg/day) |               |                |         |
| Normal       | 17 (70.8)      | 21 (80.8)      | 0.411*  |
| Low          | 7 (29.2)       | 5 (19.5)       |         |
| pH           |               |                |         |
| (RV: 6 – 7)  |               |                |         |
| Normal       | 14 (56.0)      | 21 (80.8)      | 0.057*  |
| Altered      | 11 (44.0)      | 5 (19.2)       |         |
| Urine culture|               |                |         |
| (RV: Negative) |               |                |         |
| Negative     | 23 (92.0)      | 22 (84.6)      | 0.668$^1$ |
| Positive     | 2 (8.0)        | 4 (15.4)       |         |
| Total        | 25 (100)       | 26 (100)       |         |

RV = reference value; *Chi-square test; $^1$ Fisher's exact test.
ureteral calculi or other complication(s) or sign(s) of urolithiasis.

Despite the theoretical importance of some comorbidities in the pathophysiology of nephrolithiasis, the small sample size did not allow us to draw any conclusions on these kinds of associations. However, no significant differences were observed between the cases and controls in terms of the occurrence of comorbidities.

Hypocitraturia and hypernatriuria were the main metabolic disorders identified in our study. Urinary citrate is an important inhibitor of calcium oxalate/phosphate lithogenesis. The prevalence of hypocitraturia has been estimated at 20–50%, mostly in association with other metabolic disorders (21). No established data exist on the prevalence of hypocitraturia in aging people with urolithiasis. In a retrospective study, Usui et al. found that 5% of the subjects had low urinary citrate levels, but they did not exclude subjects with a prior urolithiasis diagnosis before the age of 60 (8). In another retrospective study, Gentle et al. found that 29% of elderly individuals were hypocitraturic, and 40% of these individuals were first diagnosed with urinary lithiasis before the age of 50. In both studies, the authors were most likely analyzing chronic stone-formers who had had this condition since their third and fourth decades of life in addition to individuals who started having symptoms after 60 years of age (22). One explanation for the predominance of hypocitraturia in this age group could be specific dietary habits, including high protein and salt intake. The resultant acidic state would promote low urinary citrate excretion through proximal convoluted tubule reabsorption, balancing the intracellular pH (23). Another consequence of acidosis is bone calcium mobilization with transitory hypercalciuria, which increases the lithogenic risk of developing calcium kidney stones (24,25).

High levels of urinary sodium reduce calcium reabsorption via the proximal convoluted tubules, promoting mild systemic acidosis that increases the risk of calcium lithogenesis (26). An association often exists between high salt intake and hypocitraturia because of the resulting acidic state (27). We identified nine patients in the case arm with hypocitraturia associated with hypernatriuria, as suggested above. The ingestion of a sodium rich diet plays an important role in the formation of calcium oxalate stones, and this association may also explain the high occurrence of hypernatriuria in the case arm patients.

The hypercalciuria levels did not differ between the case and control arms. Hypercalciuria is the most common metabolic disorder in chronic stone-formers (approximately 60%) (28). The low occurrence of hypercalciuria serves as additional evidence that aging people have distinct pathophysiological features compared with younger subjects, including features related to urinary lithiasis.

Our study has several limitations. First, we did not analyze urinary oxalate levels in the 24-hour urine samples because it is not a standardized test in our clinical laboratory. Taylor et al. performed a retrospective study based on three cohorts, totaling 3,348 subjects and including both urolithiasis formers and non-formers (29), to evaluate the relationship between dietary oxalate and urinary oxalate. Diabetics and obese people presented with high levels of urinary oxalate, but an assessment of the age factor revealed that the older the individual, the more minor his/her urinary oxalate levels; in other words, an inversely proportional relationship exists between age and urinary oxalate levels (29).

The association between urolithiasis and the metabolic syndrome was not approached in this study. At the time of the conception of this study, that association had not yet well established. However, the metabolic syndrome in patients with urolithiasis seems to be more common in aging individuals than in younger individuals (30).

In conclusion, hypocitraturia and hypernatriuria are the main metabolic disorders found in aging men with urolithiasis.

ACKNOWLEDGMENTS

The authors would like to thank Stela Verzinhasse Peres (Department of Epidemiology of the University of São Paulo Public Health School), for the statistical analysis.

AUTHOR CONTRIBUTIONS

Freitas Jr CH conceived the study, defined and organized the database, evaluated the outcomes and statistical assessment, and was responsible for the literature review (discussion). Mazzucchelli conceived the study, defined and organized the database, evaluated the outcomes and statistical assessment. Danieliova A and Brito AH were responsible for critical assessment. Danilovic A and Brito AH were responsible for discussion. Mazzucchelli conceived the study, defined and organized the database, evaluated the outcomes and statistical assessment. Freitas Jr CH conceived the study, defined and organized the database, evaluated the outcomes and statistical assessment. Stoller ML, Meng MV, editors. Urinary stone disease: the practical guide to medical and surgical management. 1 ed: Humana Press Inc.; 2007. p. 27-34.

REFERENCE

1. Biggs A, Bloom D, Burlless G, Fujwara M, Hayashi K, Kanzler L, et al. A slow burning fuse: a special report on ageing populations. The Economist. 2009;27(1):1-5.
2. Dallera J, Chandhoke P. Epidemiology and incidence of stone disease. In: Stoller ML, Meng MV, editors. Urinary stone disease: the practical guide to medical and surgical management. 1 ed: Humana Press Inc.; 2007. p. 27-34.
3. Bartoletti R, Cai T, Mondaini N, Melone F, Trabaglini F, Carini M, et al. Epidemiology and risk factors in urolithiasis. Urol Int. 2007;79(Suppl 1):S7, http://dx.doi.org/10.1159/000104434.
4. Knoll T, Schubert AB, Fahlenkamp D, Leusmann DB, Wendt-Nordahl G, Schubert G. Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. J Urol. 2011;185(4):1304-11, http://dx.doi.org/10.1016/j.juro.2010.11.073.
5. Yagisawa T, Hayashi T, Yoshida A, Okuda H, Kobayashi H, Ishikawa N, et al. Metabolic characteristics of the elderly with recurrent calcium oxalate stones. BJU Int. 1999;83(9):924-8.
6. Sakhaee K. Pharmacology of stone disease. Adv Chronic Kidney Dis. 2009;16(1):30-8, http://dx.doi.org/10.1053/j.ackd.2008.10.004.
7. Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. J Urol. 1997;158(6):2221-4, http://dx.doi.org/10.1016/S0022-5347(01)68203-X.
8. Usui Y, Matsuzaka S, Matsushita K, Shima M. Urolithiasis in geriatric patients. Tokai J Exp Clin Med. 2003;28(2):81-7.
9. Worchester E, Parks JH, Josephson MA, Thisted RA, Coe FL. Causes and consequences of kidney loss in patients with nephrolithiasis. Kidney Int. 2003;64(4):2204-13, http://dx.doi.org/10.1046/j.1523-1755.2003.00317.x.
10. Ng CF, Wong A, Tolley D. Is extracorporeal shock wave lithotripsy the preferred treatment option for elderly patients with urinary stone? A multivariate analysis of the effect of patient age on treatment outcome. BJU Int. 2007;100(2):392-5.

Table 4 - Multiple logistic regression.

| Variable   | OR_adjusted | IC95%      | p-value |
|------------|-------------|-----------|---------|
| Urine citrate |             |           |         |
| Normal     | 1.0         |           |         |
| Low        | 7.12        | 1.74 – 29.21 | 0.006  |
| Urine sodium |             |           |         |
| Normal     | 1.0         |           |         |
| High       | 4.0         | 1.07 – 14.96 | 0.039  |
| Thiazide use* |             |           |         |
| No         | 1.0         |           |         |
| Yes        | 0.79        | 0.15 – 4.27 | 0.782  |

*adjusted variable.
11. Halachmi S, Meretyk S. Shock wave lithotripsy for ureteral stones in elderly male patients. Aging Male. 2006;9(3):171-4, http://dx.doi.org/10.1080/13685530600907985.

12. Ng CF. The effect of age on outcomes in patients undergoing treatment for renal stones. Curr Opin Urol. 2009;19(2):211-4, http://dx.doi.org/10.1097/MOU.0b013e328321e687.

13. Sighinolfi MC, Micali S, Grande M, Mofferdin A, De Stefani S, Bianchi G. Extracorporeal shock wave lithotripsy in an elderly population: how to prevent complications and make the treatment safe and effective. J Endourol. 2008;22(10):2223-6, http://dx.doi.org/10.1089/end.2008.9704.

14. Sumunovic D, Sudarevic B, Galic J. Extracorporeal shockwave lithotripsy in elderly: impact of age and comorbidity on stone-free rate and complications. J Endourol. 2010;24(11):1831-7, http://dx.doi.org/10.1089/end.2009.0329.

15. Anagnostou T, Thompson T, Ng CF, Moussa S, Smith G, Tolley DA. Safety and outcome of percutaneous nephrolithotomy in the elderly: retrospective comparison to a younger patient group. J Endourol. 2008;22(9):2139-45, http://dx.doi.org/10.1089/end.2007.0432.

16. Karami H, Mazloomfard MM, Golshan A, Rahjoo T, Javanmard B. Does age affect outcomes of percutaneous nephrolithotomy? Urol J. 2010 Winter;7(1):17-21.

17. Kara C, Resorlu B, Bayindir M, Unsal A. A randomized comparison of totally tubeless and standard percutaneous nephrolithotomy in elderly patients. Urology. 2010;76(2):289-93, http://dx.doi.org/10.1016/j.urology.2009.11.077.

18. Lahme S, Zimmermanns V, Hochmuth A, Liske P. Stones of the upper urinary tract. Update on minimal-invasive endourological treatment. Arch Ital Urol Androl. 2008;80(1):13-7.

19. Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K, et al. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women’s Health Initiative hormone therapy trials. Arch Intern Med. 2011;171(18):1678-85.

20. Domrongkitchaiporn S, Onghiphidadhanakul B, Stitchantrakul W, Chansirikarn S, Puavilai G, Rajatanavin R. Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen. Maturitas. 2002;41(2):149-56, http://dx.doi.org/10.1016/S0378-5122(01)00277-8.

21. Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):120-32, http://dx.doi.org/10.1016/j.smemph.2008.01.005.

22. Spivacow FR, Negri AL, del Valle EE, Calvino I, Zanchetta JR. Clinical and metabolic risk factor evaluation in young adults with kidney stones. Int Urol Nephrol. 2010;42(2):471-5, http://dx.doi.org/10.1007/s11255-009-9623-0.

23. Tracy CR, Pearle MS. Update on the medical management of stone disease. Curr Opin Urol. 2009;19(2):200-4, http://dx.doi.org/10.1097/MOU.0b013e328323a81d.

24. Hamm LL, Hering-Smith KS. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinoil Metab Clin North Am. 2002;31(4):885-93, viii, http://dx.doi.org/10.1016/S0889-8529(02)00031-2.

25. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009 Summer;11(3):134-44.

26. Stoller ML, Chi T, Eissner BH, Shami G, Gentle DL. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation. J Urol. 2009;181(3):1140-4, http://dx.doi.org/10.1016/j.juro.2008.11.020.

27. Taylor EN, Curhan GC. Demographic, dietary, and urinary factors and 24-h urinary calcium excretion. Clin J Am Soc Nephrol. 2009;4(12):1980-7, http://dx.doi.org/10.2215/CJN.02620409.

28. Worcester E, Coe F. Nephrolithiasis. Prim Care. 2008;35(2):369-91, viii.

29. Taylor EN, Curhan GC. Differences in 24-hour urine composition between black and white women. J Am Soc Nephrol. 2007;18(2):654-9, http://dx.doi.org/10.1061/AS.N.200608054.

30. West B, Luke A, Durazo-Arvizu RA, Cao G, Shobam D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis. 2008;51(5):741-7, http://dx.doi.org/10.1053/j.ajkd.2007.12.030.